MergerApr 30, 2026, 01:09 PM
DCOY Completes Merger, Changes Name, Appoints New CEO
AI Summary
Decoy Therapeutics Inc. filed an amendment to its 10-K to include Part III information, which was previously omitted. The filing details the completion of its merger with Legacy Decoy on November 12, 2025, and the subsequent legal name change from Salarius Pharmaceuticals, Inc. to Decoy Therapeutics Inc. on January 8, 2026. The company also reported two reverse stock splits and significant management changes, including the appointment of Frederick E. Pierce as CEO and Director, Barbara Hibner as CSO, and Peter Marschel as CBO, all effective November 12, 2025.
Key Highlights
- Merger transaction with Legacy Decoy completed on November 12, 2025.
- Legal name changed from Salarius Pharmaceuticals, Inc. to Decoy Therapeutics Inc. on January 8, 2026.
- 1-for-15 reverse stock split effected on August 15, 2025, and 1-for-12 split on March 6, 2026.
- Frederick E. Pierce appointed CEO and Director on November 12, 2025.
- Barbara Hibner, Ph.D., appointed Chief Scientific Officer on November 12, 2025.
- Peter Marschel appointed Chief Business Officer on November 12, 2025.
- Dr. Bruce J. McCreedy resigned from the Board of Directors on November 12, 2025.